X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Foreign investment in pharma; walking a thin line - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Oct 9, 2013

    Foreign investment in pharma; walking a thin line

    Here is today's recommended reading list from Equitymaster...

    Are strict regulations stifling investment in retail?
    Walmart put its retail venture in India on the backburner and ended its joint venture with Bharti Enterprises. The world's largest retailer cited the mandatory requirement of 30% of the product sourcing from local businesses as an impediment as it does not provide a level playing field. The opening of FDI in multi-brand retail last year has failed to attract large foreign chains due to the changed government regulations. Read on to know more... (The New York Times Company)

    Foreign investment in pharma; walking a thin line
    The 100% FDI in the pharma sector has seen a clutch of big-ticket acquisition of domestic companies by foreign multinationals since 2008. However, the health ministry is concerned that foreign companies have not invested in creating new capacities, research & development and in turn new employment in the country. Moreover, with the market share of multinationals going up in the Indian pharmaceutical markets, domestic capability will dwindle and keeping prices of essential drugs under control will become difficult. The DIPP has suggested new rules for FDI to check this. But will this dent the inflow of foreign capital in the long run. Read on to know more. (The Economist Intelligence Unit Limited)

    The conundrum of equity returns
    What factors influence the return on equity? The author of the article believes that return on equity does not depend on the GDP growth of the economy. The only reason, equity as an asset class tends to offer high returns is the significantly high risk element carried by it. Read on to know more. (GMO)

    Will US stimulus measures be pulled back soon?
    Speculations about the pullback of stimulus measures have kept global markets on the edge. However the recent development arising out of the US shutdown has lent credence to the winding up program being deferred. The US shutdown has economic costs in terms of lost growth. Therefore longer the shutdown, higher is magnitude of the losses incurred. Therefore to soften the blow, the Fed may continue its stimulus program. Apart from that factors such as absence of data during the shutdown and leadership change may lead to the stimulus program being extended until 2014, feels the author. Read on to know more... (Cable News Network)

    Is India's macro economic situation improving?
    Aided by lower imports of gold and oil coupled with jump in exports, India's trade deficit in September reduced substantially. This has increased hopes for an improvement in the country's otherwise gloomy economic outlook. Read on to find out more about this strong rebound. (Dow Jones & Company)

      Madhu Gupta (Research Analyst), Managing Editor, ResearchPro has a post graduate degree in both physics and finance. Having worked with India's leading economic research agency, she has a natural flair for numbers and analytics. She brings with her a near-decade long rich experience in the field of finance. A firm believer of the principles of value investing, she looks for robust businesses with durable competitive advantages. Madhu contributes towards our small cap service Hidden Treasure.

    Disclaimer:
    This article is for information purposes only. The link in this article will let the User leave www.equitymaster.com and proceed to the linked article. The User's use of each such site is subject to Terms of Use on www.equitymaster.com and other terms of use, if any, contained within each such site. Any data and charts if used, in the article have not been authenticated by Equitymaster and Equitymaster do not claim it to be accurate nor accept any responsibility for the same. The views, if any in the linked article are not of Equitymaster. Equitymaster will not be responsible for any loss or liability incurred to any person as a consequence of his or any other person on his behalf taking any investment decisions based on this article. Please read the detailed Terms of Use of the web site.

     

     

    Equitymaster requests your view! Post a comment on "Foreign investment in pharma; walking a thin line". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    The Power of 5 Minutes (The 5 Minute Wrapup)

    Jun 16, 2017

    Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

    Aug 10, 2017

    Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    S&P BSE HEALTHCARE


    Aug 22, 2017 09:25 AM

    MARKET STATS